Nash

Nash company information, Employees & Contact Information

Explore related pages

Related company profiles:

Self-Custody Crypto Platform and Investment App. Fully Compliant and Registered with the DNB & FMA; Secured by MPC. Fiat Ramp, Non-Custodial Wallet, High Yield Savings, DeFi Exchange, Crypto IBAN. Nash is building a next generation finance platform. A platform where Web3 & Crypto live in harmony with traditional investment tools and legacy financial products. With Nash, self-custody and decentralization interact seamlessly with traditional investing, money services, and payments. Nash helps you to fully control and manage your personal finances with a single, easy to use application. Nash is registered and founded on the belief in self-custody, decentralization and security. Invest in and self-custody all your Crypto. Instantly transfer cash from the traditional banking system to buy Crypto on a decentralized exchange. Pay expenses directly from your registered Crypto IBAN account. Generate high yields from your savings. Personal finance and investment are changing and Nash is leading the way toward self-custody and decentralization. Get the app: https://nashio.app.link/PTQB78PWrqb Join our Telegram: t.me/nashsocial
Looking for a particular Nash employee's phone or email?

Nash Questions

News

Starr Holding Company Acquires Cacher.io to Expand SaaS Portfolio and Accelerate Growth - Digital Journal

Starr Holding Company Acquires Cacher.io to Expand SaaS Portfolio and Accelerate Growth Digital Journal

Starr Holding Company Acquires Cacher.io to Expand SaaS Portfolio and Accelerate Growth - Newswire.com

Starr Holding Company Acquires Cacher.io to Expand SaaS Portfolio and Accelerate Growth Newswire.com

Novel therapies targeting bile acid-triggered pathways may benefit children with NASH - Healio

Novel therapies targeting bile acid-triggered pathways may benefit children with NASH Healio

Pegozafermin improves fibrosis in patients with NASH, could advance to phase 3 development - Healio

Pegozafermin improves fibrosis in patients with NASH, could advance to phase 3 development Healio

Endoscopic sleeve gastroplasty an effective option for patients with NASH, obesity - Healio

Endoscopic sleeve gastroplasty an effective option for patients with NASH, obesity Healio

Lead NASH contender falls short for FDA: Could NAFLD name change shift the status quo? - Healio

Lead NASH contender falls short for FDA: Could NAFLD name change shift the status quo? Healio

Quality of life, economic burden of NASH comparable, worse than type 2 diabetes - Healio

Quality of life, economic burden of NASH comparable, worse than type 2 diabetes Healio

Hepatologists, gastroenterologists lead NASH diagnosis yet ‘underdiagnosis’ persists - Healio

Hepatologists, gastroenterologists lead NASH diagnosis yet ‘underdiagnosis’ persists Healio

The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality - Healio

The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality Healio

Intercept pivots away from NASH following second FDA rejection for obeticholic acid - Healio

Intercept pivots away from NASH following second FDA rejection for obeticholic acid Healio

One-fifth of NASH patients develop cirrhosis in 4 years; lower risk for women, nonsmokers - Healio

One-fifth of NASH patients develop cirrhosis in 4 years; lower risk for women, nonsmokers Healio

Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - Healio

Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement Healio

MAESTRO-NASH topline results: Resmetirom induces NASH resolution, fibrosis improvement - Healio

MAESTRO-NASH topline results: Resmetirom induces NASH resolution, fibrosis improvement Healio

‘Unfavorable benefit-risk’: FDA panel votes against obeticholic acid approval for NASH - Healio

‘Unfavorable benefit-risk’: FDA panel votes against obeticholic acid approval for NASH Healio

FASCINATE-2 topline data: Denifanstat surpasses placebo for NASH with fibrosis at week 52 - Healio

FASCINATE-2 topline data: Denifanstat surpasses placebo for NASH with fibrosis at week 52 Healio

Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH - Healio

Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH Healio

ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48 - Healio

ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48 Healio

MAESTRO-NASH: Resmetirom 80 mg, 100 mg superior to placebo, ‘efficacious’ at 52 weeks - Healio

MAESTRO-NASH: Resmetirom 80 mg, 100 mg superior to placebo, ‘efficacious’ at 52 weeks Healio

No difference between semaglutide, placebo in fibrosis improvement in patients with NASH - Healio

No difference between semaglutide, placebo in fibrosis improvement in patients with NASH Healio

Q&A: Noninvasive liquid biopsy test could be ‘game changer’ for NASH, liver fibrosis - Healio

Q&A: Noninvasive liquid biopsy test could be ‘game changer’ for NASH, liver fibrosis Healio

Efruxifermin induces NASH resolution, improves fibrosis by at least 1 stage vs. placebo - Healio

Efruxifermin induces NASH resolution, improves fibrosis by at least 1 stage vs. placebo Healio

Intercept ‘disappointed’ after FDA setback for top NASH contender; stock drops 16% - Healio

Intercept ‘disappointed’ after FDA setback for top NASH contender; stock drops 16% Healio

Non-heavy alcohol use, total weekly consumption linked to fibrosis, NASH - Healio

Non-heavy alcohol use, total weekly consumption linked to fibrosis, NASH Healio

Resmetirom ‘has potential to be first medication approved’ for patients with NASH - Healio

Resmetirom ‘has potential to be first medication approved’ for patients with NASH Healio

Fatigue in patients with advanced NASH may increase risk for adverse events - Healio

Fatigue in patients with advanced NASH may increase risk for adverse events Healio

BIO89-100 reduces liver fat, lowers triglycerides in adults with NASH - Healio

BIO89-100 reduces liver fat, lowers triglycerides in adults with NASH Healio

Pioglitazone safe, effective in NASH treatment - Healio

Pioglitazone safe, effective in NASH treatment Healio

NEX rebrands to Nash Exchange during live "Quarterly Report" from Amsterdam - Neo News Today

NEX rebrands to Nash Exchange during live "Quarterly Report" from Amsterdam Neo News Today

DUET topline data: Terns’ THR-beta agonist drastically reduced liver fat content in NASH - Healio

DUET topline data: Terns’ THR-beta agonist drastically reduced liver fat content in NASH Healio

Progress made toward understanding best noninvasive tests for NASH, fibrosis diagnosis - Healio

Progress made toward understanding best noninvasive tests for NASH, fibrosis diagnosis Healio

Q&A: ‘Heavy, heartfelt history’ of drug trials for Black patients may fuel NASH disparities - Healio

Q&A: ‘Heavy, heartfelt history’ of drug trials for Black patients may fuel NASH disparities Healio

Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study - Healio

Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study Healio

Top in GI: Ozempic in NASH-related cirrhosis; infection risk with PPIs - Healio

Top in GI: Ozempic in NASH-related cirrhosis; infection risk with PPIs Healio

Phil A. Nash - The New Stack

Phil A. Nash The New Stack

Ocaliva down but not out: A timeline of FDA troubles for a once-promising PBC contender - Healio

Ocaliva down but not out: A timeline of FDA troubles for a once-promising PBC contender Healio

Time-restricted eating may be ‘promising management option’ in patients with NAFLD, NASH - Healio

Time-restricted eating may be ‘promising management option’ in patients with NAFLD, NASH Healio

Blood test differentiates between NAFLD, NASH - Healio

Blood test differentiates between NAFLD, NASH Healio

Ozempic boosts cardiometabolic markers, falls short for fibrosis in NASH-related cirrhosis - Healio

Ozempic boosts cardiometabolic markers, falls short for fibrosis in NASH-related cirrhosis Healio

Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial - Healio

Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial Healio

Moving Past Simple Incident Metrics: Courtney Nash on the VOID - infoq.com

Moving Past Simple Incident Metrics: Courtney Nash on the VOID infoq.com

Oracle AI agents to help automate dozens of processes as businesses seek productivity gains - Oracle

Oracle AI agents to help automate dozens of processes as businesses seek productivity gains Oracle

Liquid-Powered Interface Gives Digital Tech a Real Feel - Hackster.io

Liquid-Powered Interface Gives Digital Tech a Real Feel Hackster.io

Fatty liver disease conditions ‘change the healthy heart to a failing heart’ - Healio

Fatty liver disease conditions ‘change the healthy heart to a failing heart’ Healio

Smash-N-Nash, a new ghost kitchen from Third Street Social and Summit Grill, launches in Kansas City - Feast Magazine

Smash-N-Nash, a new ghost kitchen from Third Street Social and Summit Grill, launches in Kansas City Feast Magazine

The race is on for medical treatment of NASH - Healio

The race is on for medical treatment of NASH Healio

MASH patients with high BMI, weight respond ‘slightly better’ to higher Rezdiffra dose - Healio

MASH patients with high BMI, weight respond ‘slightly better’ to higher Rezdiffra dose Healio

Many drug therapy options exist for NAFLD - Healio

Many drug therapy options exist for NAFLD Healio

An overview of Novem AMA’s on Neo Reddit and Nash Community forum - Neo News Today

An overview of Novem AMA’s on Neo Reddit and Nash Community forum Neo News Today

Endocrinologists must screen for nonalcoholic fatty liver disease as a complication of type 2 diabetes - Healio

Endocrinologists must screen for nonalcoholic fatty liver disease as a complication of type 2 diabetes Healio

SiPEED MAIX-II Dock - Getting Started! - Hackster.io

SiPEED MAIX-II Dock - Getting Started! Hackster.io

Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis - Healio

Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis Healio

“Your business is only as good as your people”: Deborah Nash, CEO Teneo, IoD Brussels | Blogs | IoD - Institute of Directors

“Your business is only as good as your people”: Deborah Nash, CEO Teneo, IoD Brussels | Blogs | IoD Institute of Directors

New Zealand passes gun law reform in wake of Christchurch attack - Al Jazeera

New Zealand passes gun law reform in wake of Christchurch attack Al Jazeera

Australian Tesla fan blown away with FSD progress, and shares experience - The Driven

Australian Tesla fan blown away with FSD progress, and shares experience The Driven

Top 10 Hybrid Exchanges You Need to Know - Securities.io

Top 10 Hybrid Exchanges You Need to Know Securities.io

Top Nash Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant